Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 4.24
ENZ's Cash to Debt is ranked higher than
72% of the 253 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. ENZ: 4.24 )
ENZ' s 10-Year Cash to Debt Range
Min: 2.06   Max: No Debt
Current: 4.24

Equity to Asset 0.57
ENZ's Equity to Asset is ranked higher than
68% of the 233 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. ENZ: 0.57 )
ENZ' s 10-Year Equity to Asset Range
Min: 0.57   Max: 0.96
Current: 0.57

0.57
0.96
F-Score: 6
Z-Score: -0.53
M-Score: -3.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -10.61
ENZ's Operating margin (%) is ranked higher than
67% of the 247 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. ENZ: -10.61 )
ENZ' s 10-Year Operating margin (%) Range
Min: -50.6   Max: 16.64
Current: -10.61

-50.6
16.64
Net-margin (%) -10.40
ENZ's Net-margin (%) is ranked higher than
66% of the 247 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.07 vs. ENZ: -10.40 )
ENZ' s 10-Year Net-margin (%) Range
Min: -39.34   Max: 17.67
Current: -10.4

-39.34
17.67
ROE (%) -28.62
ENZ's ROE (%) is ranked higher than
61% of the 225 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. ENZ: -28.62 )
ENZ' s 10-Year ROE (%) Range
Min: -56.99   Max: 9
Current: -28.62

-56.99
9
ROA (%) -16.63
ENZ's ROA (%) is ranked higher than
63% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. ENZ: -16.63 )
ENZ' s 10-Year ROA (%) Range
Min: -43.97   Max: 8.6
Current: -16.63

-43.97
8.6
ROC (Joel Greenblatt) (%) -87.70
ENZ's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. ENZ: -87.70 )
ENZ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -229.37   Max: 33.95
Current: -87.7

-229.37
33.95
Revenue Growth (%) -5.40
ENZ's Revenue Growth (%) is ranked higher than
64% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. ENZ: -5.40 )
ENZ' s 10-Year Revenue Growth (%) Range
Min: -9.9   Max: 24.4
Current: -5.4

-9.9
24.4
EBITDA Growth (%) -16.10
ENZ's EBITDA Growth (%) is ranked higher than
62% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. ENZ: -16.10 )
ENZ' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 157.1
Current: -16.1

0
157.1
EPS Growth (%) -12.20
ENZ's EPS Growth (%) is ranked higher than
67% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.50 vs. ENZ: -12.20 )
ENZ' s 10-Year EPS Growth (%) Range
Min: -24.6   Max: 58.7
Current: -12.2

-24.6
58.7
» ENZ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ENZ Guru Trades in Q4 2013

Jim Simons 345,637 sh (+21.75%)
» More
Q1 2014

ENZ Guru Trades in Q1 2014

Jim Simons 447,881 sh (+29.58%)
» More
Q2 2014

ENZ Guru Trades in Q2 2014

Jim Simons 563,818 sh (+25.89%)
» More
Q3 2014

ENZ Guru Trades in Q3 2014

Dodge & Cox 15,570 sh (New)
Jim Simons 928,800 sh (+64.73%)
» More
» Details

Insider Trades

Latest Guru Trades with ENZ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Dodge & Cox 2014-09-30 New Buy$4.55 - $6.08 $ 4.5-16%15570
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.29
ENZ's P/B is ranked higher than
65% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.45 vs. ENZ: 5.29 )
ENZ' s 10-Year P/B Range
Min: 0.85   Max: 7.13
Current: 5.29

0.85
7.13
P/S 1.96
ENZ's P/S is ranked higher than
81% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. ENZ: 1.96 )
ENZ' s 10-Year P/S Range
Min: 0.56   Max: 15.23
Current: 1.96

0.56
15.23
EV-to-EBIT -18.09
ENZ's EV-to-EBIT is ranked higher than
60% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ENZ: -18.09 )
ENZ' s 10-Year EV-to-EBIT Range
Min: -72.1   Max: -1.1
Current: -18.09

-72.1
-1.1
Current Ratio 1.63
ENZ's Current Ratio is ranked higher than
59% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.55 vs. ENZ: 1.63 )
ENZ' s 10-Year Current Ratio Range
Min: 1.36   Max: 33.47
Current: 1.63

1.36
33.47
Quick Ratio 1.28
ENZ's Quick Ratio is ranked higher than
54% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.12 vs. ENZ: 1.28 )
ENZ' s 10-Year Quick Ratio Range
Min: 1   Max: 32.01
Current: 1.28

1
32.01

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 55.50
ENZ's Price/Net Current Asset Value is ranked higher than
78% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ENZ: 55.50 )
ENZ' s 10-Year Price/Net Current Asset Value Range
Min: 4.11   Max: 60
Current: 55.5

4.11
60
Price/Tangible Book 9.25
ENZ's Price/Tangible Book is ranked higher than
68% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.49 vs. ENZ: 9.25 )
ENZ' s 10-Year Price/Tangible Book Range
Min: 1.97   Max: 17.2
Current: 9.25

1.97
17.2
Price/Median PS Value 0.83
ENZ's Price/Median PS Value is ranked higher than
88% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.34 vs. ENZ: 0.83 )
ENZ' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 11.89
Current: 0.83

0.24
11.89
Earnings Yield (Greenblatt) -5.50
ENZ's Earnings Yield (Greenblatt) is ranked higher than
63% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. ENZ: -5.50 )
ENZ' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -5.5

Forward Rate of Return (Yacktman) -13.59
ENZ's Forward Rate of Return (Yacktman) is ranked higher than
57% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.70 vs. ENZ: -13.59 )
ENZ' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -34.9   Max: 18.1
Current: -13.59

-34.9
18.1

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, IDXX » details
Traded in other countries:EZB.Germany
Enzo Biochem Inc was founded in 1976. It is engaged in research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally. The Company is conducting research and development activities in the development of therapeutic products based on the Companys technology platform of genetic modulation and immune modulation. The Company also operates a clinical laboratory that offers and provides diagnostic medical testing services to the health care community in the New York Metropolitan and New Jersey areas. The Company operates in three segments of which the Therapeutics and Life Sciences segments have evolved out of its core competencies. enzo Life Sciences manufactures, develops and markets functional biology and cellular biochemistry products and tools to research and pharmaceutical customers world-wide and has amassed a large patent and technology portfolio, enzo Clinical Labs is a regional clinical laboratory serving the New York Metropolitan and New Jersey areas, enzo Therapeutics is a biopharmaceutical venture that has developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of enzo Life Sciences. The Company has developed a portfolio of proprietary technologies with research, diagnostic and therapeutic applications. It is applying its core technologies to develop novel therapeutics as well as research tools for the life sciences and clinical diagnostics markets. In addition, The Company provides clinical laboratory services to physicians and other health care providers in the New York Metropolitan and New Jersey area. The Company is organized to the development, production, marketing and sales of life science research reagents. The products supplied by Enzo Life Sciences include small molecules, proteins, antibodies, peptides, assay kits and custom services. Enzo Life Sciences is organized to promote and market its product through its seven brands Enzo, Alexis, Apotech, Axxora, Biomol, Assay Designs and Stressgen. Therapeutic Development Programs include Autoimmune Uveitis, Inflammatory bowel diseases. Osteoporosis (and certain bone disorders) and Diabetes, Non-Alcoholic SteatoHepatitis (NASH) and Human Immunodeficiency Virus (HIV-1). The Company competes with other life science and biotechnology companies, as well as pharmaceutical, chemical and other companies. The clinical laboratory industry is subject to federal and state regulation, including inspections and audits by governmental agencies.
» More Articles for ENZ

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BWEN, DDMG, ZHNE, ENZ, SIRO Nov 28 2011 
Weekly CFO Buys Highlight: BWEN, ENZ, PIP, HAFC, AACC Nov 21 2011 
Enzo Biochem Inc. Reports Operating Results (10-Q) Mar 14 2011 
Enzo Biochem Inc. Reports Operating Results (10-Q) Dec 10 2010 
Enzo Biochem Inc. Reports Operating Results (10-Q) Jun 09 2010 
Enzo Biochem Inc. Reports Operating Results (10-Q) Dec 10 2009 
Weekly Top Insider Buys: Bank of America Corp., Safeway Inc., Umpqua Holdings Corp., National Penn B Oct 24 2009 
Weekly Top Insider Buys: KB Home, National Penn Bancshares Inc., Moduslink Global Solutions Inc., En Oct 20 2009 
Enzo Biochem Inc. Reports Operating Results (10-Q) Sep 04 2009 
Enzo Biochem Inc. (ENZ) Files Quarterly Report for the Period Ended on 2008-10-31 Dec 15 2008 

More From Other Websites
What Falling Estimates & Price Mean for Enzo Biochem (ENZ) Oct 17 2014
ENZO BIOCHEM INC Financials Oct 16 2014
Enzo Biochem Inc Earnings Call scheduled for 8:30 am ET today Oct 10 2014
ENZO BIOCHEM INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Oct 09 2014
Enzo Biochem Reports Strong Fiscal Fourth Quarter Results Oct 09 2014
Q4 2014 Enzo Biochem Inc Earnings Release - After Market Close Oct 09 2014
Enzo Biochem Awarded Patent for Novel Vectors Involving Gene Therapy Treatments for Cancer, Virus... Oct 07 2014
Enzo Biochem Schedules Teleconference to Discuss Fourth Quarter Results Friday, October 10, 2014 at... Oct 06 2014
Cambrex Corporation (CBM) in Focus: Stock Up 7.3% Aug 04 2014
Thomas C Wright, MD, World Recognized Women’s Health Sciences Authority, Joins Enzo Biochem’s... Jul 31 2014
Strength Seen in Aegerion Pharmaceuticals, Inc. (AEGR): Stock Shoots up 16.4% Jul 31 2014
Enzo Biochem Announces August 18, 2014 as Date of Markman Hearing in Patent Infringement Lawsuit... Jul 29 2014
Enzo Biochem Added to Russell 2000 and Russell 3000 Indexes Jun 30 2014
ENZO BIOCHEM INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Jun 23 2014
Earnings Estimates Moving Higher for Enzo Biochem (ENZ): Time to Buy? Jun 17 2014
ENZO BIOCHEM INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jun 09 2014
Enzo Biochem Reports Strong Third Fiscal Quarter Results Jun 09 2014
Enzo Biochem Awarded U.S. Patent on More Efficient Vector for Use in Gene Therapy Jun 06 2014
Enzo Biochem Schedules Teleconference to Discuss Third Quarter Results Tuesday, June 10, 2014 at... Jun 03 2014
Enzo Biochem Announces Appointment of James M. O’Brien as Senior VP, Finance May 30 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK